

# CITATION REPORT

List of articles citing

## Nivolumab Plus Relatlimab: First Approval.

DOI: 10.1007/s40265-022-01723-1  
Drugs, 2022, , 1.

**Source:** <https://exaly.com/paper-pdf/145310833/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
32	Metastasis of Melanoma to the Adrenal Glands: A Case Report and Literature Review. <i>Cureus</i> , <b>2022</b> ,	1.2	
31	Educational Review: Neoadjuvant Approaches to Melanoma. <i>Annals of Surgical Oncology</i> ,	3.1	0
30	pH-sensitive nanomedicine of novel tubulin polymerization inhibitor for lung metastatic melanoma. <b>2022</b> , 350, 569-583		0
29	Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy. <b>2022</b> , 20, 5150-5161		0
28	Therapeutic plasma exchange in the management of immune checkpoint inhibitor-associated immune-related adverse effects: A review.		1
27	The Potential of Antibody Technology and Silver Nanoparticles for Enhancing Photodynamic Therapy for Melanoma. <b>2022</b> , 10, 2158		0
26	Emerging Trends in Immunotherapy for Cancer. <b>2022</b> , 10, 60		1
25	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. 13,		0
24	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <b>2022</b> , 15,		1
23	Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy. <b>2022</b> , 113, 109365		0
22	Evolving therapeutic landscape of advanced hepatocellular carcinoma.		0
21	Tumor immunophenotyping-derived signature identifies prognosis and neoadjuvant immunotherapeutic responsiveness in gastric cancer.		0
20	Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents.		0
19	Proteomic profiling of a patient with cutaneous melanoma metastasis regression following topical contact sensitizer diphencyprone and immune checkpoint inhibitor treatment. <b>2022</b> , 12,		1
18	Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. <b>2023</b> , 24, 41		1
17	Case report: Later onset of NRAS-mutant metastatic melanoma in a patient with a partially-excised giant congenital melanocytic nevus. 9,		0
16	Approach to the Patient With Immune Checkpoint Inhibitor-Associated Endocrine Dysfunction.		1

- 15 The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy. **2022**, 10, 3154 ○
- 14 Tumor-Infiltrating T Cells in EBV-Associated Gastric Carcinomas Exhibit High Levels of Multiple Markers of Activation, Effector Gene Expression, and Exhaustion. **2023**, 15, 176 1
- 13 Comparison of efficacy and tolerability of adjuvant therapy for resected high-risk stage III-IV cutaneous melanoma: a systemic review and Bayesian network meta-analysis. **2023**, 15, 175883592211489 ○
- 12 Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer. 9, ○
- 11 Immune checkpoint blockades therapy of melanoma. **2023**, 68, 356-358 ○
- 10 Boosting Checkpoint Immunotherapy with Biomaterials. **2023**, 17, 3225-3258 ○
- 9 Nivolumab/relatlimab in advanced melanoma: a profile of its use. **2023**, 39, 89-95 ○
- 8 Mucocutaneous adverse events to immune checkpoint inhibitors. 4, ○
- 7 Trendbericht Organische Chemie 2023. **2023**, 71, 40-66 ○
- 6 PD-1/LAG-3 Dysfunctionality Signatures in Human Cancers. ○
- 5 A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022. ○
- 4 Tumor Immunophenotyping-Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer. ○
- 3 The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma. ○
- 2 Regulatory Mechanisms and Reversal of CD8+T Cell Exhaustion: A Literature Review. **2023**, 12, 541 ○
- 1 Inside PD-1/PD-L1,2 with their inhibitors. **2023**, 256, 115465 ○